Axsome Therapeutics (NASDAQ: AXSM) — Company Overview, News & Financial Data
Axsome Therapeutics develops novel therapies for central nervous system disorders to improve patient outcomes.
Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system disorders. The company's commercial portfolio includes Auvelity, an oral N-methyl-D-aspartate receptor antagonist indicated for major depressive disorder, and Sunosi, a wake-promoting agent prescribed for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Axsome is also advancing a late-stage clinical pipeline targeting conditions such as Alzheimer's disease agitation, fibromyalgia, migraine, narcolepsy, and smoking cessation. Its proprietary drug development platforms utilize innovative mechanisms of action and multimodal pharmacology to address unmet medical needs in neuroscience.
Snapshot
Operations
Products and/or services of Axsome Therapeutics
- Major Depressive Disorder Therapies: Commercialized oral N-methyl-D-aspartate receptor antagonist and dextromethorphan-bupropion combination treatment formulated to target major depressive disorder in adult patients across pharmaceutical markets in the United States.
- Excessive Daytime Sleepiness Products: Commercialized dual dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients experiencing excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea across global medical markets.
- Alzheimer's Disease Agitation Candidates: Late-stage investigational NMDA receptor antagonist formulation in Phase 3 clinical trials evaluated for the management and reduction of agitation associated with Alzheimer's disease in geriatric patient populations.
- Acute Migraine Treatment Programs: Late-stage investigational oral co-formulation of rizatriptan and meloxicam designed for rapid absorption and sustained pain relief in adult patients suffering from acute migraine attacks with or without aura.
- Fibromyalgia Therapeutics Pipeline: Investigational selective serotonin-norepinephrine reuptake inhibitor candidate in Phase 3 development designed to reduce widespread chronic musculoskeletal pain, fatigue, and sleep disturbances in adult patients suffering from fibromyalgia across clinical treatment settings.
- Narcolepsy and Sleep Disorder Candidates: Investigational highly selective histamine H3 receptor antagonist and inverse agonist in Phase 3 development targeting excessive daytime sleepiness, cataplexy, and cognitive symptoms in patients with narcolepsy.
Axsome Therapeutics executive team
- Dr. Herriot Tabuteau M.D.Founder, Chairman, CEO & President
- Mr. Nick Pizzie CPA, M.B.A.Chief Financial Officer
- Mr. Mark L. Jacobson M.A.Chief Operating Officer
- Mr. Hunter Murdock Esq.General Counsel & Secretary
- Mr. Ari MaizelChief Commercial Officer
- Darren OplandDirector of Corporate Communications